ContraFect Corp (NASDAQ:CFRX)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - CFRX

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - CFRX

  • Market Cap$154.180m
  • SymbolNASDAQ:CFRX
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS2123263004

Company Profile

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.ContraFect Corp is a biotechnology company engaged in the development of protein and antibody therapeutic products for life-threatening infectious diseases. The Company's product candidates are CF-301, CF-404.

Latest CFRX news

Currently there for this company. Visit our news hub for other news .